Chemotherapy: What progress in the last 5 years?

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1760-1775

  Hamilton, Anne ^a   Hortobagyi, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ALOPECIA; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INJECTION SITE REACTION; LEUKEMOGENESIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; STOMATITIS; BREAST TUMOR; DRUG THERAPY; FEMALE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG THERAPY; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 15544389499     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.034     Document Type: Review

References (150)

1. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17:2341-2354, 1999
2. Jones S, Erban J, Overemoyer B, et al: Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 82:59, 2004 (abstr 10; suppl 1).
3. Tabernero J, Climent MA, Lluch A, et al: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365, 2004
4. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724-733, 2000
5. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068, 2004
6. Seidman A, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly (w) paclitaxel via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER-2 positive metastatic breast cancer and randomized for T in HER-2 normal MBC. Proc Am Soc Clin Oncol 22:6s, 2004 (abstr 512)
7. Bruno S, Puerto VL, Mickiewicz E, et al: Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18:392-396, 1995
8. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
9. Garcia-Conde J, Lluch A, Martin M, et al: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854-857, 1994
10. Gasparini G, Caffo O, Barni S, et al: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12:2094-2101, 1994
11. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336-341, 1994
12. Terenziani M, Demicheli R, Brambilla C, et al: Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 39:285-291, 1996
13. Twelves CJ, Dobbs NA, Curnow A, et al: A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990-993, 1994
14. Vogel C, O'Rourke M, Winer E, et al: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10:397-402, 1999
15. Weber BL, Vogel C, Jones S, et al: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995
16. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
17. Freyer G, Delozier T, Lichinister M, et al: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35-40, 2003
18. Gabizon A, Catane R, Uziely B, et al: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992, 1994
19. O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449, 2004
20. Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451, 1998
21. Hamilton A, Biganzoli L, Coleman R, et al: EORTC 10968: A phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol 13:910-918, 2002
22. Safra T, Muggia F, Jeffers S, et al: Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029-1033, 2000
23. Rivera E: Liposomal anthracyclines in metastatic breast cancer: Clinical update. Oncologist 8:3-9, 2003 (suppl 2)
24. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36, 2002
25. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
26. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
27. Scheithauer W, McKendrick J, Begbie S, et al: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743, 2003
28. Frickhofen N, Beck FJ, Jung B, et al: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13:797-801, 2002
29. Blackstein M, Vogel CL, Ambinder R, et al: Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 62:2-8, 2002
30. Possinger K, Kaufmann M, Coleman R, et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10:155-162, 1999
31. Spielmann M, Llombart-Cussac A, Kalla S, et al: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60:303-307, 2001
32. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
33. Smorenburg CH, Bontenbal M, Seynaeve C, et al: Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66:83-87, 2001
34. Grunewald R, Kantarjian H, Du M, et al: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
35. Tempera M, Plunkett W, Ruiz VH, V, Hainsworth J, Hochster H, Lenzi R et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003
36. Schmid P, Akrivakis K, Flath B, et al: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625-631, 1999
37. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439-3460, 1998
38. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
39. Albain K, Nag S, Calderillo-Ruiz G, et al: Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc Am Soc Clin Oncol 22:5s, 2004 (abstr 510)
40. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer. An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003
41. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
42. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
43. Jahanzeb M, Mortimer JE, Yunus F, et al: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7:410-417, 2002
44. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
45. Tedesco KL, Thor AD, Johnson DH, et al: Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22:1071-1077, 2004
46. Pegram MD, Pienkowski T, Northfelt DW, et al: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759-769, 2004
47. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
48. Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337-356, 1968
49. Fisher B: Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer. Cancer 24:1286-1289, 1969
50. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 319:1681-1692, 1988
51. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339:1-15, 1992
52. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
53. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
54. 53a. Albain K, Green J, Ravdin P, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100. Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
55. Hortobagyi GN: Progress in systemic chemotherapy of primary breast cancer: An overview. J Natl Cancer Inst Monogr 30:72-79, 2001
56. Cocconi G: Chemotherapy with and without anthracycline. J Clin Oncol 18:1392-1393, 2000
57. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
58. Poole CJ, Earl HM, Dunn JA, et al: NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 22:4, 2003 (abstr 13)
59. Hortobagyi GN: High-dose chemotherapy for primary breast cancer: Facts versus anecdotes. J Clin Oncol 17:25-29, 1999
60. Henderson I, Berry D, Demetri G, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
61. Mamounas E, Bryant J, Fehrenbacher P, et al: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 22:4, 2003 (abstr 12)
62. Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002
63. Nabholtz JM, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 141)
64. Martin M, Pienkowski T, Mackey J, et al: TAC improves disease-free survival and overall survival over FAC in node-positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 76:2a, 2003 (abstr 43; suppl 1)
65. Verweij J, Clavel M, Chevallier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5:495-505, 1994
66. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
67. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
68. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14:35-45, 1996
69. Misset JL, di Raima M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145, 1996
70. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
71. Buzdar AU, Gutterman JU, Blumenschein GR, et al: Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 41:1064-1075, 1978
72. Jones SE, Savin MA, Asmar L, et al: Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (Pts) with stage I-III operable, invasive breast cancer comparing 4 courses of adriamycin/ cyclophosphamide (AC) to 4 courses of taxotere/cyclophosphamide (TC). Proc Am Soc Clin Oncol 22:15, 2003 (abstr 59)
73. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: First report of Inter-group Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
74. Miles D, von Minckwitz G, Seidman AD: Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7:13-19, 2002
75. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307-1317, 1977
76. Haskell CM, Green SJ, Sledge GW, et al: Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with O - 3 positive nodes (intergroup 0137). Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 142)
77. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
78. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
79. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003
80. Hortobagyi GN, Singletary SE, Strom EA: Treatment of locally advanced and inflammatory breast cancer, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the breast. Philadelphia, PA, Lippincott Williams and Wilkins; 2000, pp 645-660
81. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
82. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
83. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from NSABP B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
84. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
85. Feldman L, Hortobagyi G, Buzdar A, et al: Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578-2581, 1986
86. Kuerer H, Newman L, Smith T, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
87. Kuerer H, Sahin A, Hunt K: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230:72-78, 1999
88. Bear H, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 21:4165-4174, 2003
89. Pierga J, Mouret E, Dieras V, et al: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83:1480-1487, 2000
90. Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994
91. Makris A, Powles TJ, Ashley SE, et al: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179-1184, 1998
92. Smith I, Heys S, Hutcheon A, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
93. von Minckwitz G, Raab G, Schuette M, et al: Dose-dense versus sequential adriamycin/ docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0)-primary endpoint analysis of the GEPARDUO-study. Proc Am Soc Clin Oncol 21:43a, 2002 (abstr 168)
94. Untch M, Konecny G, Ditsch N, et al: Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 133)
95. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 20:33a, 2002 (abstr 135)
96. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003
97. Hutcheon AW, Heys SD, Sarkar TK, et al: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat 82:S9, 2003 (suppl 1)
98. Dittrich C, Jakesz R, Gnant M, et al: Preoperative paclitaxel (TOL) in the first-line therapy of patients with breast cancer T 3/4, N 0-30, M 0, followed by surgery, CMF +/-tamoxifen and radiotherapy: Phase II trial. Proc Am Soc Clin Oncol 16:166a, 1997 (abstr 581)
99. Volm M, Formenti S., Symmans F., et al: Neo-adjuvant paclitaxel for locally advanced breast cancer (LABC): Preliminary results. Proc Am Soc Clin Oncol 17:180a, 1998 (abstr 695)
100. Formenti SC, Spicer D, Skinner K, et al: Paclitaxel alone and in combination with radiation therapy as neoadjuvant approach to locally advanced breast cancer (LABC): Clinical and pathological response. Proc Am Soc Clin Oncol 20:39b, 2001 (abstr 1902)
101. Kimura M: Weekly paclitaxel as neoadjuvant chemotherapy (NAC) for breast cancer (BC). Proc Am Soc Clin Oncol 22:77, 2003 (abstr 307)
102. Moliterni A, Tarenzi E, Capri G, et al: Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 24: S17-10-S17-14, 1997
103. Moliterni A, Tagliabue P, Tarenzi E, et al: Non-randomized comparison between primary chemotherapy (PC) with single anthracycline (A) or doxorubicin + paclitaxel (AT). Proc Am Soc Clin Oncol 19:93a, 2000 (abstr 357)
104. Pouillart P, Fumoleau P, Romieu G, et al: Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide and doxorubicin/Taxol (paclitaxel) as neoadjuvant treatment of local-regional breast cancer. Proc Am Soc Clin Oncol 18:73a, 1999 (abstr 275)
105. Anelli A, Gadelha AP, Albuquerque AA, et al: High response rate of paclitaxel (PTX) and doxorubicin (DOC) as neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (IIIB) is associated with p53 status. Proc Am Soc Clin Oncol 18:80a, 1999 (abstr 302)
106. Semiglazov VF, Bojok AA, Arsumanov AS, et al: Neoadjuvant chemotherapy paclitaxel and doxorubicin (PD) versus fluorouracil and doxorubicin and cyclophosphamide (FAC) in locally advanced breast cancer: Clinical and pathological response. Eur J Cancer 37:S166, 2001 (abstr 606; suppl 6)
107. Alvarez A, Rodger J, Brosio C, et al: Neoadjuvant chemotherapy for stage III breast cancer: Does the addition of paclitaxel to doxorubicin increase complete response-A single institution non-randomised study. Eur J Cancer 38:S73, 2002 (abstr 134; suppl 3)
108. Romieu G, Tubiana-Hulin M, Fumoleau P, et al: A multicenter randomised phase II study of 4 or 6 cycles of Adriamycin/Taxol (paclitaxel) AT as neoadjuvant treatment of breast cancer (BC). Ann Oncol 13:33-34, 2002 (abstr 118; suppl 5)
109. Ghilezan N, Vitoc C, Tanasscu R, et al: Epidoxorubicin and paclitaxel combination in neoadjuvant setting for stage IIB-IIIA breast cancer. Preliminary results. Proc Am Soc Clin Oncol 18:94a, 1999 (abstr 354)
110. Bellino R, Cortese P, Danese S, et al: Primary chemotherapy with sequential epidoxorubicin (E)/paclitaxel (P) combination INT2 >3cm-T4 breast cancer patients: A phase II study. Proc Am Soc Clin Oncol 19:131a, 2000 (abstr 514)
111. Koenig E, Warm M, Breidenbach M, et al: Neoadjuvant chemotherapy with paclitaxel and epirubicin in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 21:53b, 2002 (abstr 2022)
112. Bertone E, Danese S, Richiardi G, et al: Weekly concomitant administration of epidoxorubicin and paclitaxel as primary chemotherapy for T2 (>3 cm)-T4d breast cancer patients. Proc Am Soc Clin Oncol 22:72, 2003 (abstr 288)
113. Chen SC, Chang HK, Lin YC, et al: Neoadjuvant chemotherapy with biweekly epirubicin and paclitaxel for locally advanced breast cancer. Proc Am Soc Clin Oncol 22:58, 2003 (abstr 231)
114. Ezzat A, Rahal M, Bazarbashi S, et al: High complete pathological response (CpR) induced by circadian Taxol (T) and cis-platinum (P) in locally advanced breast cancer (ABC). Proc Am Soc Clin Oncol 16:168a, 1997 (abstr 586)
115. Ezzat A, Rahal M, Raja MA, et al: Pathologic response to paclitaxel-cisplatin versus 5 fluorouracil, doxorubicin, cyclophosphamide primary chemotherapy in locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 17:139a, 1998 (abstr 531)
116. Buzzi F, D'Aiuto G, Comelia P, et al: Short-term dose-dense weekly cisplatin-epirubicin-paclitaxel (PET) administration with granulocyte-colony stimulating factor (G-CSF) support in large operable breast cancer. SICOG 0105 phase II study. Proc Am Soc Clin Oncol 22:83, 2003 (abstr 333)
117. van Praagh I, Amat S, Leduc B, et al: Induction chemotherapy in operable breast cancer by NET regimen: Multicentre phase II trial. Ann Oncol 13:5, 2002 (abstr 153)
118. Conte PF, Gennari A, Santoro A, et al: Induction chemotherapy in operable breast cancer: A multicenter Italian phase II study with the GET regimen. Proc Am Soc Clin Oncol 22:35, 2003 (abstr 140)
119. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Huntingt) 11:15-18, 1997 (8 suppl 8)
120. Amat S, Bougnoux P, Penault-Llorca F, et al: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88:1339-1345, 2003
121. von Minckwitz G, Costa SD, Eiermann W, et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005, 1999
122. Dorr VJ, Standiford S, Ford L, et al: A pilot multimodality study with pre-operative and post-operative chemotherapy with Taxotere (docetaxel) and Adriamycin (doxorubicin) (TA) for locally advanced breast cancer. Proc Am Soc Clin Oncol 18:92a, 1999 (abstr 346)
123. Lara F, De La Garza J, Ramirez T, et al: High pathological complete response (PCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Proc Am Soc Clin Oncol 19:126a, 2000 (abstr 492)
124. Marcus E, Burt S, Shiomoto G, et al: The safety of doxorubicin and docetaxel in a phase II trial of neoadjuvant treatment of locally advanced breast cancer. Proc Am Soc Clin Oncol 18:98a, 1999 (abstr 369)
125. Valero V, Esteva FJ, Rosales MF, et al: Phase II trial of primary chemotherapy with docetaxel and doxorubicin in locally advanced breast cancer: Clinical and pathological results. Proc Am Soc Clin Oncol 19:132a, 2000 (abstr 519)
126. Evans T, Gould A, Foster E, et al: Phase III randomised trial of adriamycin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy in women with breast cancer: An ACCOG study. Proc Am Soc Clin Oncol 21:35a, 2002 (abstr 136)
127. Steger GG, Wenzel C, Djavanmard MP, et al: Preoperative docetaxel/epidoxorubicin (DE) in primary breast cancer. Proc Am Soc Clin Oncol 18:118a, 1999 (abstr 448)
128. Luporsi E, Vanlemmens L, Coudert B: 6 cycles of FEC 100 vs. 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: Preliminary results of a randomized phase II trial of GIREC S01. Proc Am Soc Clin Oncol 19:92a, 2000 (abstr 355)
129. Wachters B, Annemie P, Ines D, et al: Efficacy and tolerance of epirubicin-docetaxel (E-T) in patients with inflammatory breast cancer. Breast Cancer Res Treat 69:301, 2001 (abstr 519)
130. Milla A, Morales S, Burrillo MA, et al: High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study. Breast Cancer Res Treat 69:271, 2001 (abstr 359)
131. Hurley J, Doliny P, Gomez C, et al: High complete pathologic response rate of locally advanced breast cancer (LABC) to neoadjuvant (NEO) docetaxel and cisplatin chemotherapy. Proc Am Soc Clin Oncol 19:127a, 2000 (abstr 494)
132. Hurley J, Doliny P, Velez P, et al: High rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and cisplatin in locally advanced and inflammatory breast cancer. Breast Cancer Res Treat 69:300, 2001 (abstr 516)
133. Lamenting SA, Brusly AM, Urban JK, et al: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Breast Cancer Res Treat 82:S55, 2003 (abstr 240; suppl 1)
134. Yardley DA, Whitworth P, Greco FA, et al: Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer. Breast Cancer Res Treat 82:554, 2003 (abstr 237; suppl 1)
135. Schneeweiss A, Geberth M, Sinn HP, et al: The triplet gemcitabine, epirubicin, and docetaxel as primary systemic chemotherapy in primary breast cancer T2-4, N0-2, M0: Final primary endpoint analysis of a multicentric phase I/II trial. Breast Cancer Res Treat 82:S56, 2003 (abstr 242; suppl 1)
136. Molucon C, Vanlemmens L, Chollet P, et al: Pathological complete response with neoadjuvant (NA) chemotherapy (trastuzumab (T) and docetaxel (D)) in HER2 positive (3+) locally advanced (LA) breast cancer (BC) patients. Breast Cancer Res Treat 82:S59, 2003 (abstr 253; suppl 1)
137. Minton SE, Garcia R, Bowman T, et al: A phase II neoadjuvant trial of sequential doxorubicin and docetaxel for the treatment of stage III breast cancer measuring signal transducers and activators of transcription (STAT) activation as a predictor of response to therapy. Breast Cancer Res Treat 69:300, 2001 (abstr 514)
138. Blohmer JU, Paepke S, Fleige U, et al: Dose-intensified, sequential preoperative chemotherapy with epirubicin and docetaxel in patients with inoperable and non metastatic breast cancer: A prospective, controlled, multicenter phase II study. Proc Am Soc Clin Oncol 18:89a, 1999 (abstr 333)
139. Miller KD, McCaskill-Stevens W, Sisk J, et al: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999
140. von Minckwitz G, Raab G, Schuette M, et al: Dose-dense versus sequential adriamycin/ docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0)-primary endpoint analysis of the GEPARDUO-study. Proc Am Soc Clin Oncol 21:43a, 2002 (abstr 168)
141. Link JS, Forsthoff CA, Ibarra J, et al: Dose-dense doxorubicin, docetaxel and cyclophosphamide as sequential neoadjuvant therapy for high-risk breast cancer: A pilot study. Breast Cancer Res Treat 82:S59, 2003 (abstr 254; suppl 1)
142. Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in Operable breast cancer (ECTO): Effects of primary systemic therapy on local-regional disease. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 132)
143. Jackisch C, von Minckwitz G, Costa S et al: Adapting in-vivo- chemosensitivity for further evaluation of preoperative chemotherapy in patients with operable primary breast cancer. Interim analysis of the gepartrio-trial. Breast Cancer Res Treat 82:S51, 2003 (abstr 228; suppl 1)
144. Buzdar AU, Valero V, Theriault RL, et al: Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 82:569, 2003 (abstr 302; suppl 1)
145. Untch M, Kahlert S, Moebus V, et al: Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer (BC)-results of a randomised trial. Proc Am Soc Clin Oncol 22:9, 2003 (abstr 35)
146. Gonzalez-Angulo AM, Kau SW, Broglio K, et al: Invasive lobular carcinoma (ILC) "Classic Type": Distinct clinical features. Proc Am Soc Clin Oncol 23:28, 2004 (abstr 663)
147. Mathieu MC, Rouzier R, Llombart-Cussac A, et al: The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40:342-351, 2004
148. Hortobagyi GN, Hayes DF, Pusztai L: Integrating newer science into breast cancer prognosis and treatment: A review of current molecular predictors and profiles. Proc Am Soc Clin Oncol 21:192-201, 2002
149. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
150. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003